Onxeo offre 10,7% de son capital à Invus – Biotech Finances

(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]

• 2020
• Financials and Corporate
• Media
• Uncategorized

Tags: Financials & Corporate

06/15/2020

BFM Business Intégrale Bourse : Onxeo, Company of the Day

  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

• 2020
• AsiDNA™
• Financials and Corporate
• Media
• Uncategorized

Tags: AsiDNA™, Financials & Corporate

06/10/2020

Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder

The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022                 Paris […]

• 2020
• Financial operations
• Press releases

Tags: Financials & Corporate

06/09/2020

Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions

The Extraordinary General Meeting will be held on June 19, 2020 on the second call   Paris (France), May 29, […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

05/29/2020

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

• 2020
• AsiDNA™
• Press releases

Tags: AsiDNA™

Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation

Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

05/27/2020

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• AsiDNA™
• Press releases

Tags: AsiDNA™

05/19/2020

Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information

Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

• 2020
• General meetings
• Press releases

Tags: Financials & Corporate, General meetings

05/07/2020

Publication of the 2019 Universal Registration Document

Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/27/2020

Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update

Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]

• 2020
• Financials and Corporate
• Press releases

Tags: belinostat / Beleodaq

04/17/2020